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Summary
Background Inflammation has a key role in the pathogenesis of psoriasis. Circulat-
ing cell-free DNA (CFD) is a marker of tissue cell damage closely associated with
inflammation.
Objectives We aimed to understand the relation of CFD levels with psoriasis sever-
ity, defined by the Psoriasis Area and Severity Index (PASI), with inflammation
and with psoriasis therapy.
Methods Forty-six patients with psoriasis vulgaris were evaluated before (T0) and
after 12 weeks (T12) of treatment with narrowband ultraviolet light B (NB-UVB;
n = 17), psoralen plus UVA (PUVA; n = 20) or topical therapy (n = 9). We eval-
uated interleukin (IL)-6 and circulating CFD levels.
Results Compared with controls, at T0, patients presented significantly higher lev-
els of circulating CFD. CFD presented a significant positive correlation with IL-6
and a trend towards a positive correlation with PASI. Multiple linear regression
analysis identified IL-6 as an independent variable associated with CFD circulating
levels. As shown by the PASI score, a trend towards higher values of CFD was
observed in the severe psoriasis forms; moderate and severe psoriasis presented
also significantly higher CFD values, compared with control. Both NB-UVB and
PUVA treatments significantly decreased the levels of CFD.
Conclusions Patients with psoriasis, at the active stage of the disease, presented an
increased inflammation associated with raised circulating CFD levels, which seem
to be linked to psoriasis severity. Both NB-UVB and PUVA, anti-inflammatory
therapies, were effective in decreasing CFD values. We propose that the evalua-
tion of circulating CFD may provide a new biomarker to monitor psoriasis, its
severity and its treatment.
What’s already known about this topic?
• Circulating cell-free DNA (CFD) levels, a marker associated with inflammation, has
never been evaluated in psoriasis.
What does this study add?
• At the active stage of psoriasis, patients presented an increased inflammation associ-
ated with raised circulating CFD levels, which seem to be linked to psoriasis severity.
• NB-UVB and PUVA, anti-inflammatory therapies, were effective in decreasing CFD
values.
• The evaluation of circulating CFD may provide a new biomarker to monitor psoria-
sis, its severity and its treatment.
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Marked chronic inflammation is a hallmark of psoriasis, asso-
ciated with a rise in several inflammatory biomarkers.1–4
Increasing psoriasis severity has been associated with an
enhancement in the inflammatory response.3
Circulating cell-free DNA (CFD) appears following cell dam-
age and DNA release, and its levels are increased in pathologi-
cal processes characterized by marked inflammation.5–7 In
patients on haemodialysis, CFD levels were associated with
inflammation8 and positively correlated with interleukin (IL)-
6.7,8 We found that IL-6 levels are increased in psoriasis and
correlate with the Psoriasis Area and Severity Index (PASI).9
Considering the inflammatory and hyperproliferative psoria-
sis features and that, as far as we know, CFD levels have not
been evaluated in psoriasis, we thought it important to evalu-
ate them.
Our aim was to quantify circulating CFD levels in a Portu-
guese psoriatic population, in order to search for a relation-
ship with inflammation and severity of the disease, and to
study the relation of CFD with the efficacy of the therapy
used.
The protocol used was approved by the Committee on Eth-
ics of the University Hospital of Coimbra, Portugal.
Forty-six patients with psoriasis vulgaris were clinically and
analytically studied in the active phase of the disease (T0) and
12 weeks (T12) after starting treatment. Seventeen patients
were treated with narrowband ultraviolet light B (NB-UVB),
20 with psoralen plus UVA (PUVA) and nine with topical
therapy. The control group included 20 healthy volunteers
without psoriasis or other skin disease and with normal hae-
matological and biochemical values. Protocol treatments and
inclusion/exclusion criteria used were reported previously.9
Circulating CFD was detected directly in serum samples
using a rapid direct fluorescent assay, according to Goldshtein
et al.10 IL-6 levels were evaluated by enzyme-linked immuno-
sorbent assay (Human IL-6 ELISA, Bender MedSystems,
Vienna, Austria). Psoriasis severity was evaluated by PASI.11
Clinical and analytical data for controls and patients with
psoriasis are presented in Table 1. At the active stage of psori-
asis, we found that exacerbation of the lesions and of the
inflammatory process were associated with increasing CFD lev-
els, compared with controls. After successful treatment, dem-
onstrated by the significant PASI reduction (Table 1), CFD
levels decreased significantly. As previously reported,9 at T0
we found that IL-6 levels were enhanced, and decreased sig-
nificantly after treatment. The CFD increase seems to be linked
to the inflammatory response, as CFD values were positively
correlated with the inflammatory marker IL-6 (Fig. 1a),
known to be raised in active psoriasis. Moreover, in multiple
linear regression analysis (using stepwise selection) Lg10 IL-6
remained significantly associated with Lg10 CFD (b = 0225;
P = 00001), identifying IL-6 as an independent variable asso-
ciated with CFD levels. CFD was reported to be able to selec-
tively induce IL-6 production by monocytes,12 which may
justify its association with the inflammatory response.
Whether CFD is a consequence of inflammation in psoriasis,
or itself contributes to the inflammatory process is not known.
Leaking of DNA fragments from the nuclei of leucocytes was
reported as the possible source of CFD in patients on haemo-
dialysis.12 In psoriasis, the origin of CFD has not been identi-
fied and might result from different inflammatory cells
involved in psoriasis lesions.
At T0, NB-UVB [172 (126–250); median (interquartile
range)] and PUVA [249 (133–335)] patients presented sig-
nificantly higher PASI (P ≤ 0001 and P ≤ 0001, respectively)
than topical patients [81 (67–105)]; at T12, the topical
group [36 (26–68)] presented significantly higher PASI
scores (P = 0023) than the PUVA group [16 (08–39)], but
not significantly different from the NB-UVB group [31
(16–66)]. According to the PASI score, all treatments were
successful as a decrease was found for NB-UVB, PUVA and
topical therapy (P ≤ 0001, P ≤ 0001 and P = 0008, respec-
tively). Patients treated with NB-UVB and PUVA showed,
before treatment, significantly higher CFD values, compared
with controls; patients undergoing topical therapy presented
only a trend towards higher CFD values (P = 0085). After
treatment, the CFD levels decreased significantly for patients
Table 1 Clinical and analytical data for controls and patients with psoriasis vulgaris, before (T0) and at end of therapy (T12)
Control (n = 20)
Psoriasis vulgaris patients (n = 46)
T0 T12
Age (years) 424  163 446  157 –
Sex (F/M) 11/9 24/22 –
Smoking habits (s/ns) 5/15 8/38 –
BMI (range) (kg m2) 256 (235–296) 282 (252–297) –
ToDsD (years) – 188  117 –
PASI – 166 (105–266) 28 (14–48)c
Cell-free DNA (range) (ng mL1) 336 (247–475) 518 (370–701)a 449 (319–522)d
Interleukin-6 (range) (pg mL1) 045 (021–066) 110 (060–222)b 095 (036–161)e,f
To compare control with patients at T0 and T12, we used the Mann–Whitney U-test; to evaluate differences between T0 and T12, we used
the Wilcoxon test; measurements are expressed as mean  SD, or as median values (interquartile ranges). s, smoker; ns, nonsmoker; BMI,
body mass index; ToDsD, time of disease since diagnosis; PASI, psoriasis area and severity index. aP (T0 vs. control) ≤ 0001; bP (T0 vs.
control) ≤ 0001; cP (T0 vs. T12) ≤ 0001; dP (T0 vs. T12) ≤ 0001; eP (T0 vs.T12) = 0002; fP (T12 vs. control) = 0015.
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treated with NB-UVB and PUVA and a trend towards lower
values was found for topically treated patients (Fig. 1b–d).
Concerning IL-6, a significant reduction was observed after
treatment for PUVA group, as reported.9
The significant decrease in CFD levels observed after therapy
strengthens its linkage to inflammatory cell damage; indeed,
this reduction was associated with a decrease in inflammation
and in psoriasis lesions, as shown by a decrease in IL-6 and
PASI, respectively. PUVA and NB-UVB therapies, used to treat
moderate and severe forms of psoriasis, are known to present
anti-inflammatory and immunomodulatory activities,13 and to
be associated with a reduction in inflammatory markers.3,4,9,14
They were clearly successful therapies, as confirmed by the
significant decrease in PASI, and for both we observed similar
modifications, a decrease in CFD levels, which is in accordance
with a reduction in the inflammatory state. We found no sig-
nificant changes in CFD with topical therapy. Topical agents,
used for the mildest forms of psoriasis, act locally and seem
to present a less marked anti-inflammatory activity.
According to the PASI score, at T0, 10 of the patients pre-
sented mild (score below 10), 18 moderate (score between
10 and 20) and 18 severe (score above 20) psoriasis.15 The
severe and moderate forms of psoriasis presented significantly
higher values of CFD, compared with controls (P = 0012 and
P = 0001, respectively), and a trend towards higher values
was observed for the mild form. The same pattern was found
for IL-6, as previously reported.9
Increasing psoriasis severity was associated with a signifi-
cantly higher inflammatory degree, as shown by IL-6 values.
Although circulating CFD presented only a trend towards
higher values with increasing psoriasis severity (r = 0234;
P = 0117), we found a positive significant correlation with
IL-6 (r = 0303; P = 0041), suggesting an association of
worsening of psoriasis and inflammation with an increase in
inflammatory cell damage and, therefore, in circulating CFD.
Indeed, compared with controls, patients in the NB-UVB and
PUVA groups presented higher CFD values at T0 and, when
compared with patients in the topical group, the NB-UVB and
(a) (b)
(c) (d)
Fig 1. (a) Correlation found for psoriasis vulgaris patients between cell-free DNA (ng mL1) and interleukin-6 (pg mL1). Values of circulating
cell-free DNA (ng mL1) for control and patients with psoriasis according to treatment with (b) narrowband ultraviolet light B (NB-UVB), (c)
psoralen plus UVA (PUVA) and (d) topical therapy. The Spearman coefficient correlation was calculated. To compare groups according to therapy
and severity, we used one-way ANOVA supplemented with Tukey post hoc test (after linearization of variables, when necessary).
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PUVA groups presented higher PASI scores. At T0, the topical
group showed milder psoriasis, as defined by PASI, and did
not present significant differences in CFD from the control
group, before and after treatment. Further studies in a larger
population are warranted, in order to confirm our data sug-
gesting that circulating CFD levels are associated with the
severity of psoriasis.
In summary, patients with psoriasis, at the active stage of
the disease, present an increased inflammation associated with
raised circulating CFD levels, which seem to be linked to pso-
riasis severity. Both NB-UVB and PUVA, anti-inflammatory
therapies, were effective in decreasing CFD values. We pro-
pose that the evaluation of circulating CFD, using an assay that
is easy to perform and not expensive, may provide a new bio-
marker to monitor psoriasis, its severity and its treatment.
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